Introduction
Extracellular vesicles (EVs), including exosomes, are emerging as key mediators of intercellular communication, transferring bioactive molecules such as microRNAs, proteins, and lipids. Among non-neuronal cells, Schwann cells, oligodendrocytes, and satellite glial cells (SGCs) release EVs with distinct neuroprotective and pain-relieving properties. These EVs play critical roles in modulating inflammation, supporting neuronal repair, and regulating pain pathways, offering innovative therapeutic avenues for chronic pain management and neural repair.
Methods
A scoping review was conducted by systematically searching the PubMed, Scopus, and Web of Science databases. Studies published up to November 2024 were screened to identify evidence on Schwann cell-, oligodendrocyte-, and SGC-derived EVs. A total of 15 key studies were included, focusing on their cargo, functional mechanisms, and therapeutic applications.
Results
Schwann cell-derived EVs are enriched with neuroprotective microRNAs such as miR-21 and miR-146a, which reduce pain by regulating inflammation and promoting neuronal survival. They also carry proteins like brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), enhancing neuronal repair. Oligodendrocyte-derived EVs deliver proteins such as myelin basic protein (MBP) and proteolipid protein (PLP), which are essential for neuronal stability and repair, as well as superoxide dismutase (SOD), which mitigates oxidative stress. SGC-derived EVs, while also carrying miR-21 and miR-146a, modulate neuronal hyperexcitability and inflammation uniquely through cytokines such as interleukin-10 (IL-10), amplifying their pain-relieving effects.
Conclusion
This review highlights the distinctive roles of Schwann cell-, oligodendrocyte-, and SGC-derived EVs in alleviating pain and supporting neural health. It identifies key research gaps, including the need for standardized methodologies and deeper characterization of EV cargo. These findings emphasize the therapeutic potential of EVs as innovative tools for chronic pain treatment and neural regeneration, underscoring their translational value for future research and clinical applications.
I would like to know what specific molecules or signalling pathways are involved in the contribution of small extracellular vesicles from schwann cells and satellite glial cells to pain processing?
Regarding the specific molecules and signaling pathways: sEVs derived from Schwann cells and SGCs can carry a range of bioactive molecules, including microRNAs (like miR-21 and miR-146a), cytokines (e.g., TNF-α, IL-6), and neurotrophic factors (such as NGF and BDNF). These components have been shown to modulate nociceptive signaling by interacting with neurons and immune cells.
In terms of signaling pathways, key players often include NF-κB pathway, which is activated in inflammatory responses and can influence pain sensitivity; MAPK/ERK pathway, important for nociceptor sensitization, and PI3K/Akt pathway, which may contribute to neuroprotective effects and cell survival.
Of course, this area is still emerging, and the exact mechanisms can vary depending on the injury model or disease context.
Thanks again for engaging with my poster.
